Klaus Schmierer
Queen Mary University of London
H-index: 52
Europe-United Kingdom
Top articles of Klaus Schmierer
Prospective Longitudinal Study of Cladribine Tablets (CLADB Study) Demonstrates Sustained Reduction in Kappa Free Light Chains in Relapsing Multiple Sclerosis (RRMS) at 96 …
2024/4/14
Jonathan Bestwick
H-Index: 26
Monica Marta
H-Index: 17
Klaus Schmierer
H-Index: 32
David Baker
H-Index: 117
Comparing the Pathology, Clinical, and Demographic Characteristics of Younger and Older‐Onset Multiple Sclerosis
Annals of Neurology
2024/3
MS care: integrating advanced therapies and holistic management
2024/1/30
Klaus Schmierer
H-Index: 32
Antonio Scalfari
H-Index: 13
Cladribine tablets in Relapsing-Remitting Multiple Sclerosis preferentially target B-cells
medRxiv
2024
Investigation of Changes in Lymphocyte Subset Counts and their Relationship with MRI Outcomes in the Magnify-MS Study
Multiple Sclerosis and Related Disorders
2023/12/1
Parakinesia Brachialis Oscitans in a Patient With a First Manifestation of Multiple Sclerosis
Neurology: Clinical Practice
2023/12
Klaus Schmierer
H-Index: 32
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis
Therapeutic Advances in Neurological Disorders
2023/11
Honing in on magnetic resonance imaging predictors of multiple sclerosis pathology
Brain Pathology
2023/11
Klaus Schmierer
H-Index: 32
Anaesthetic management of people with multiple sclerosis
2023/10/11
Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices
The Patient-Patient-Centered Outcomes Research
2023/9
Organic solvents and Multiple Sclerosis: the doubled risk dilemma
Occupational Medicine
2023/8/1
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination
Multiple Sclerosis Journal
2023/7
Efficacy in Clinical and MRI Outcomes With Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis (MAGNIFY-MS)
2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers
2023/6/1
Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study (S16. 006)
2023/4/25
Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS …
2023/4/25
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets
2023/2
Klaus Schmierer
H-Index: 32
Heinz Wiendl
H-Index: 55
Celia Oreja-Guevara
H-Index: 36
Diego Centonze
H-Index: 16
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination
2023/1/1
Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis
Mult Scler Relat Disord
2023/12/22
David Baker
H-Index: 117
Klaus Schmierer
H-Index: 32
Personalised immunotherapy in active multiple sclerosis using injectable cladrib-ine: Follow-up of the BartsMS cohort
2022/6/1
178 Atraumatic lumbar puncture campaign–effect on complications
Journal of Neurology, Neurosurgery and Psychiatry
2022/6/1
Klaus Schmierer
H-Index: 32
Co-Authors
